CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Urovant Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Urovant Sciences Ltd
Suite 1
3rd Floor, 11-12 St. James s Square
Phone: (949) 226-6029p:949 226-6029 London, CA  SW1Y 4LB  United Kingdom
This company was Merged or Acquired on 3/29/2021.
This company ceased filing statements with the SEC on 4/8/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20203/31/2020YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer & Director Keith A.Katkin
Chairman of the Board Myrtle S.Potter 61 8/1/2018 7/1/2018
Senior Vice President & Chief Accounting Officer Christine G.Ocampo
17 additional Officers and Directors records available in full report.

Business Names
Business Name
UROV
Urovant Holdings Limited
Urovant Sciences Treasury, Inc.
Urovant Sciences, Inc.
Urovant Treasury Holdings, Inc.

General Information
Number of Employees: 70 (As of 3/31/2020)
Outstanding Shares: 32,743,396 (As of 2/11/2021)
Shareholders: 2
Stock Exchange: NASD


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023